Target intelligence / Profile preview

Bacterial fatty acid synthase (type II) (FAS (type II); sometimes referred to as FASII)

Target
FAS (type II); sometimes referred to as FASII
Molecular classification
Enzyme (includes Acetyl-CoA carboxylase, 3-ketoacyl-ACP synthases, enoyl-ACP reductases, etc.), Biosynthetic pathway, Transferase (acyltransferases), Reductase (enoyl-ACP reductase FabI, FabL, etc.)
01

Overview

Bacterial fatty acid synthesis is an essential metabolic pathway utilizing a collection of discrete enzymes to assemble fatty acids from acetyl-CoA precursors, extending them two carbons at a time via iterative reactions[1][4][5]. Key components include acetyl-CoA carboxylase, 3-ketoacyl-ACP synthases (FabB, FabF), reductases (FabG, FabI), and acyl carrier protein (ACP)[1][4][5]. This pathway differs significantly from mammalian fatty acid synthesis ("type I") and offers several points of vulnerability for antibiotic development, as the enzymes involved are structurally distinct and required for bacterial cell membrane formation[2][5]. Drug resistance can arise due to environmental fatty acid scavenging and enzymatic redundancy, complicating therapeutic interventions[2].

Other names
Fatty acid synthesis pathway (type II)FASIIBacterial fatty acid synthase system
02

Mechanism of action

Enzyme inhibition (preventing successive steps in fatty acid elongation) Preventing reduction (inhibition of reductase enzymes like FabI) Blocking substrate activation (e.g., inhibiting acyl-acyl carrier protein synthetase)

03

Biological functions

Fatty acid biosynthesisMembrane lipid synthesisEnergy storageCell membrane integrity
04

Disease associations

Infection (antibiotic resistance and susceptibility depend on this pathway)Other (potential for broad-spectrum antimicrobial development)
05

Safety considerations

Bacteria may bypass FAS inhibition by scavenging exogenous fatty acids, limiting drug efficacyOff-target effects in host fatty acid metabolism (if drugs are insufficiently selective)Resistance development (alternative enzymes or pathways can emerge)
06

Interacting drugs

Triclosan (FabI inhibitor)

3 more in the full profile.

07

Biomarkers

Expression levels of FabI, FabF, ACP (for pathway activity and drug sensitivity)

Beyond the preview

Go deeper on Bacterial fatty acid synthase (type II) (FAS (type II); sometimes referred to as FASII).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bacterial fatty acid synthase (type II) (FAS (type II); sometimes referred to as FASII).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call